Do I Need Biomarker Testing Before Choosing Lung Cancer Treatment?

Name: Do I Need Biomarker Testing Before Choosing Lung Cancer Treatment?
Creator: Cancer Next Step

Direct answer

Often biomarker testing should be considered before lung cancer treatment decisions when results could change which options your team discusses. The importance and timing of testing depend on cancer type, stage, treatment options being considered, and what information is still missing. It may not change the plan if results are already complete or would not alter the next step. Ask: which tests matter for my cancer, and should we wait for results before choosing treatment?

Reviewed for structure, accuracy, and source alignment. Educational information only — not a diagnosis or treatment recommendation. Sources

Not sure this is your step? Start from your situation →

Decision Path

Biomarker Testing Decision Path

Why it matters → whether options could change → what you may go through → what to ask your doctor.

1
Understand the decision
Why does lung cancer biomarker testing matter?
Patient question: why is my doctor talking about this test?
Before making treatment decisions, ask whether the picture is complete.
After a lung cancer diagnosis, many people want to move quickly toward treatment — and some choices depend on understanding more about the cancer itself.
Biomarker testing looks for features of your cancer
Some results may open or change treatment discussions
Treatment decisions are stronger when important information is available
The important question is not:
“Do I need every possible test?”
The more useful question is:
“Do I have the information needed to make a treatment decision?”
Ask your care team whether testing is complete and whether results could change the options you should discuss.
Path question
What is lung cancer biomarker testing?
A plain-language definition.
Biomarker testing looks for features of your cancer that may affect which treatments your care team discusses.
It is laboratory analysis — often using tissue or other samples already collected. It is related to, but not the same thing as, a biopsy procedure.
Some results may open or change treatment discussions; others mainly confirm that the current plan still fits the information available.
Path question
What does lung cancer biomarker testing look for?
Features of your cancer — not a gene encyclopedia.
The test looks for features of your cancer — signals that may help doctors compare which approaches are worth discussing for you.
Exactly which features matter depends on your cancer type, stage, and the decision in front of you. That list belongs in a conversation with your care team, not on a public webpage.
Ask: “For my situation, what are we looking for — and could the answer change the options we discuss?”
Path question
I was recently diagnosed with lung cancer — does this apply?
When testing comes up after a new diagnosis.
New diagnosis
You may be asking:
Do I know enough about my cancer yet?
Is important information still missing before we choose?
Path question
I’m choosing lung cancer treatment — does this apply?
When results may change options before locking a plan.
Choosing treatment
You may be asking:
Could results change the options on the table?
Should testing happen before locking a plan?
Path question
My lung cancer plan changed or I want another opinion
When updated testing may matter again.
Treatment change or another opinion
You may be asking:
Was all relevant information reviewed?
Would updated testing change what we compare next?
Path question
Does everyone with lung cancer need the same biomarker tests?
Why testing is not identical for every person.
Does everyone need the same tests?
No. Not every person with lung cancer needs the same tests at the same time — and asking about testing is not the same as being “upsold.”
What is useful depends on your cancer type, stage, the treatment decision in front of you, and what information is already available.
Your care team may weigh factors such as:
Cancer type and subtype
Stage and how quickly a first treatment decision is needed
Whether results could change the options under discussion
What testing has already been completed
A useful question: “For my situation, which tests matter before we choose a plan — and which can wait?”
Questions you may have
2
Compare what matters
Could biomarker results change my lung cancer treatment options?
Patient question: what would this result actually be used for?
Results may change which approaches your team discusses. A biomarker finding does not automatically mean a specific treatment — and it is only one factor among several. Decisions still consider:
Treatment decisions may also depend on:
Cancer stage · Overall health · Previous treatments · Treatment goals · Potential benefits and trade-offs · Personal preferences
If no “actionable” finding is reported, that does not mean there are no options — it means this particular information did not point to a specific matched approach. Ask what the next discussion should focus on.
Results may support discussions about certain therapies, comparisons among options, or clinical trials — or they may mainly confirm that the current plan still fits the information available.
Testing improves the information for discussion — it does not replace a conversation with your care team.
Path question
Does a lung cancer biomarker result mean targeted therapy?
What a finding may open — and what it does not decide alone.
Not automatically. A biomarker finding may open a discussion about matched approaches — including targeted therapies in some situations — but it does not by itself choose the right treatment.
Ask: “If this result is positive, what options does it add — and what still depends on other factors?”
Path question
What if lung cancer has no targetable mutation?
Why “no match” is not the same as “no options.”
If no “actionable” finding is reported, that does not mean there are no options — it means this particular information did not point to a specific matched approach. Ask what the next discussion should focus on.
Ask: “If there is no actionable finding, what should our next conversation focus on?”
Path question
Which lung cancer biomarkers are usually checked?
Ask what matters for your decision — not a public gene list.
There is no single public checklist that fits every person. Useful tests depend on cancer type, stage, prior results, and the treatment decision you are making now.
Ask: “Which tests matter before we choose a plan — which are already done — and which can wait?”
Questions you may have
3
Consider practical realities
What should I know before lung cancer biomarker testing?
Patient question: what will I actually go through?
Real decisions include the practical layer — not only whether this path could help, but what you may need to go through.
How a sample would be obtained — existing tissue, sometimes blood, sometimes a new biopsy discussion
Rough timing — when results are expected, and whether treatment decisions will wait
Cost and insurance questions to ask before anything is ordered
Open a question beside this step for details that match your worry.
Path question
How is lung cancer biomarker testing done?
Tissue already collected, blood tests, or a new sample.
Biomarker testing is laboratory analysis of cancer features. It is not the same thing as a biopsy — though it often uses tissue or other samples already collected, or sometimes a new sample.
Tissue already collected
Many tests use pathology samples from a prior biopsy or surgery, if enough usable material remains.
Blood-based testing (liquid biopsy)
In some situations, doctors discuss blood tests that look for cancer-related signals. Availability and usefulness depend on the clinical context.
A new sample, if needed
If prior tissue is insufficient or outdated for the decision at hand, another biopsy may be discussed. That is a separate procedure decision.
Path question
Do I need another biopsy for lung cancer biomarker testing?
When a new sample may be discussed — and when it may not.
Not always. Ask whether existing samples can be used first.
If a new biopsy is recommended, ask why it is needed now, what it would change, and what the alternatives are if waiting or using other sample types.
Path question
What are the biopsy risks for lung cancer biomarker testing?
Risks usually come from getting tissue, not the lab test itself.
The main risks usually come from obtaining new tissue — not from the laboratory biomarker analysis itself. Procedure risks depend on how and where a sample would be taken.
Bleeding or bruising at the procedure site
Infection (uncommon, but possible with invasive procedures)
Pain or discomfort during recovery
Procedure-specific risks your team should explain for the planned approach
Ask: “If we need new tissue, what are the risks in my case, and how do those trade off against the information we might gain?”
Path question
How long does biomarker testing take for lung cancer?
What affects turnaround — without a fixed calendar.
How long does biomarker testing take?
There is no single calendar for every test. Turnaround depends on the type of test, where it is performed, whether a usable sample is already available, and whether another sample is needed.
Timing often depends on:
Whether existing tissue or a blood sample can be used
Which tests are ordered and which laboratory runs them
Local processing and shipping time
Whether an additional biopsy is needed first
Ask your care team:
Has my sample already been sent for testing?
When should we expect results in our setting?
Will treatment decisions wait for these results — and why or why not?
Do not assume “waiting” always means unsafe delay — or that results will arrive overnight. Confirm both the expected window and how it affects the next decision.
Path question
What does “comprehensive” lung cancer biomarker testing mean?
Broad panels vs limited tests — and what to confirm was checked.
“Comprehensive” usually means a broad panel that looks for many cancer features at once — not only one or two markers in lung cancer.
Limited testing may miss options that a broader panel could surface
Tissue amount, cancer type, and stage can affect what is ordered
Your team should be able to say what was tested and what was not
Ask:
Was comprehensive testing ordered for my situation?
If not, what would change if we broadened the panel?
Path question
Has my tumor been tested for the lung cancer biomarkers that matter?
A direct question that belongs in your next visit.
This is one of the most useful early questions after a lung cancer diagnosis.
Ask:
Has my tumor been tested for the biomarkers that matter for my decision?
Which results are back, and which are still pending?
Would any pending result change the options we discuss?
You do not need a gene list — you need clarity on whether key information is already available.
Path question
Should I wait for biomarker results before starting lung cancer treatment?
Waiting is not automatically an unsafe delay.
Does biomarker testing mean delaying treatment?
One of the most common concerns after diagnosis is whether waiting for more information will delay care.
“Will waiting for more information delay my care?”
Important factors may include:
Cancer type and stage
How quickly treatment decisions need to be made
What information is still needed
A useful question to ask your care team
“Could waiting for these results change the treatment options we should consider?”
The answer depends on your individual situation. Discuss timing directly with your care team.
Path question
Lung cancer care: cost and insurance
Questions to ask before testing is ordered.
Cost and insurance — what to ask before testing is ordered
There is no single “typical price.” Cost depends on the test type, lab, country or system, insurance rules, and whether another procedure is needed. Use these questions instead of guessing a number.
Which tests are being ordered, and why does each one matter for this decision?
What is usually covered, what needs prior authorization, and what might we pay out of pocket?
If cost is a barrier, can existing tissue, a narrower panel, or another path still answer the key question?
Practical pair to ask together: “What will this cost us — and will the result change what we discuss next?”
Questions you may have
4
Prepare for next conversation
What should I discuss with my doctor for lung cancer?
Patient question: what should I ask at the next visit?
Take to your appointment
Doctor Conversation Checklist
Before leaving your appointment, ask:
Has biomarker testing been completed?
Are all recommended results available?
Could results change my treatment options?
Should we wait for results before deciding treatment?
Add items to your prep sheet— Copy/Print includes this list plus any questions you added below.
More questions by situation
Before testing
What biomarkers should be tested for my cancer type and situation?
Has my tissue or sample already been sent — or can you use what we already have?
Do I need another biopsy, and what are the risks if we do?
What should we expect for cost, insurance, and turnaround time?
Before choosing treatment
Should we wait for results before locking a plan?
Could these results change my options?
What happens if results are not back yet but treatment pressure is rising?
If testing is incomplete or unclear
Are the results complete for the decision we are making now?
What if there is no actionable finding?
Are there other ways to get the information we still need?
How should these results change our next step?
Path question
Mistake: treating all lung cancers the same
Why one-size-fits-all thinking can mislead.
Assuming all lung cancers are treated the same
Why it matters: Different cancers may have different characteristics that influence treatment discussions.
Path question
Mistake: choosing before checking missing info for lung cancer
Why locking a plan too early can narrow options.
Choosing treatment before asking whether important information is missing
Why it matters: Some decisions may depend on having complete information.
Path question
Mistake: assuming testing always delays care for lung cancer
Why waiting for information is not always unsafe delay.
Thinking more testing always means unnecessary delay
Why it matters: The purpose of testing is not to slow decisions. The purpose is to avoid making important choices without relevant information.
Path question
Mistake: treating one result as the whole decision for lung cancer
Why results are one factor among several.
Treating one test result as the entire decision
Why it matters: Good decisions consider medical information together with personal goals and preferences.
Path question
An example lung cancer decision scenario
How someone might frame this decision.
Example: Deciding whether more information is needed before treatment
Illustrative decision scenarioNot a real patient story
A person receives a lung cancer diagnosis and is presented with treatment options.
Before choosing a treatment, they ask whether additional testing could provide information that changes the discussion.
They focus on:
•What is already known
•What information is still missing
•Whether test results could affect available options
•What questions to ask their care team
The goal is not to delay decisions. The goal is to make decisions with the most relevant information available.
Questions you may have

You've completed this decision step

Why biomarker testing matters
How results may affect choices
What to consider before testing
Questions to ask your doctor

Continue after this decision

Your next step

One clear move after this page — not a new reading list.

Compare Lung Cancer Treatment Options →

Treatment Comparison Decision Center

Saved questions for your visit? Open your prep sheet →

Also related

Optional — only if these fit your situation.

Sources & Review Information

Reviewed sources and medical references supporting this decision guide.

View sources

Medical information sources

This page is informed by publicly available cancer guidance from NCCN, NCI, ASCO/Cancer.Net, and ESMO. Entry-specific references are listed below.

National Comprehensive Cancer Network (NCCN)
National Cancer Institute (NCI)
American Society of Clinical Oncology (ASCO / Cancer.Net)
European Society for Medical Oncology (ESMO)

References

NCCN Patient Guidelines overview resources — NCCN
Non-Small Cell Lung Cancer Treatment (PDQ) — Patient Version — National Cancer Institute
Lung Cancer — Patient Information — Cancer.Net / ASCO
ESMO Patient Guides — Lung Cancer — European Society for Medical Oncology

Content review

Content last checked:: July 15, 2026
Creation:: AI-assisted content creation
Editorial review:: Reviewed for structure, accuracy, and source alignment
Medical information reviewed against:: Current clinical guidelines and publicly available patient education resources; Not physician-medically reviewed unless a named medical reviewer is listed.
Purpose:: Decision support and patient preparation
Not:: Diagnosis or medical advice

Medical information disclaimer

This content provides educational information and does not replace professional medical advice, diagnosis, or treatment. Always discuss decisions with your clinicians.

See our Trust & Disclaimer for how content is prepared.

Do I Need Biomarker Testing Before Choosing Lung Cancer Treatment?

Why does lung cancer biomarker testing matter?

Could biomarker results change my lung cancer treatment options?

What should I know before lung cancer biomarker testing?

What should I discuss with my doctor for lung cancer?